What is Amgen Inc. (AMG.DE)?

Amgen Inc. (AMG.DE) is a stock in the Healthcare sector, Drug Manufacturers - General industry. View full analysis on Stocks360.

Amgen Inc. (AMG.DE)

Stock analysis · XETRA · Healthcare · Drug Manufacturers - General

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

0.41

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

Amgen Inc. (AMG.DE) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 4, 2026

EPS $5.51 vs est. $4.92

Beat by $0.59

Proprietary Signals

Signal snapshot temporarily unavailable.

About Amgen Inc.

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, operates globally as a biopharmaceutical company focused on discovering, developing, manufacturing, and delivering human therapeutics. The firm concentrates its research and development efforts on critical therapeutic areas such as inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Its extensive product portfolio includes a range of impactful medicines. Examples feature Enbrel for autoimmune conditions like psoriasis and arthritis, Neulasta to mitigate infection risk in cancer patients with low white blood cell counts, Prolia for postmenopausal osteoporosis, and Repatha to decrease the likelihood of heart attack, stroke, and coronary revascularization. Other key offerings include Xgeva, Otezla, Aranesp, and KYPROLIS, among numerous additional treatments like Nplate, Vectibix, and Aimovig. Amgen distributes its products through pharmaceutical wholesalers and direct-to-consumer channels, serving a wide array of healthcare providers, including physicians, clinics, hospitals, and pharmacies. The company actively pursues strategic collaborations to advance…